Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Literature
1.
Iatridi F, Theodorakopoulou MP, Papagianni A, Sarafidis P (2022) Management of intradialytic hypertension: current evidence and future perspectives. J Hypertens 40:2120–2129CrossRefPubMed
2.
Iatridi F, Theodorakopoulou MP, Karpetas A, Sgouropoulou V, Georgiou A, Karkamani E et al (2023) Association of intradialytic hypertension with future cardiovascular events and mortality in hemodialysis patients: effects of ambulatory blood pressure. Am J Nephrol 54:299–307CrossRefPubMed
3.
Iatridi F, Theodorakopoulou MP, Papagianni A, Sarafidis P (2022) Intradialytic hypertension: epidemiology and pathophysiology of a silent killer. Hypertens Res 45:1713–1725CrossRefPubMed
4.
Rubinger D, Backenroth R, Sapoznikov D (2012) Sympathetic activation and baroreflex function during intradialytic hypertensive episodes. PLoS ONE 7:e36943CrossRefPubMedPubMedCentral
5.
Park SH, Fonkoue IT, Li Y, DaCosta DR, Middlekauff HR, Park J (2018) Augmented cardiopulmonary baroreflex sensitivity in intradialytic hypertension. Kidney Int Rep 3:1394–1402CrossRefPubMedPubMedCentral
6.
7.
Inrig JK, Van Buren P, Kim C, Vongpatanasin W, Povsic TJ, Toto R (2012) Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction. Clin J Am Soc Nephrol 7:1300–1309CrossRefPubMedPubMedCentral
8.
Bikos A, Loutradis C, Angeloudi E, Karpetas A, Raptis V, Kalaitzidis R et al (2019) The effects of nebivolol and irbesartan on postdialysis and ambulatory blood pressure in patients with intradialytic hypertension: a randomized cross-over study. J Hypertens 37:432–442CrossRefPubMed
9.
Loutradis C, Bikos A, Raptis V, Afkou Z, Tzanis G, Pyrgidis N et al (2019) Nebivolol reduces short-term blood pressure variability more potently than irbesartan in patients with intradialytic hypertension. Hypertens Res 42:1001–1010CrossRefPubMed
10.
Theodorakopoulou M, Loutradis C, Bikos A, Angeloudi E, Schoina M, Raptis V et al (2021) The effects of nebivolol and irbesartan on ambulatory aortic blood pressure and arterial stiffness in hemodialysis patients with intradialytic hypertension. Blood Purif 50:73–83CrossRefPubMed
11.
Chandra A, Rao N, Srivastava D, Mishra P (2021) Better peridialytic blood pressure control using carvedilol in end stage renal disease patients on twice weekly maintenance hemodialysis. Int Urol Nephrol 53:1007–1014CrossRefPubMed
12.
13.
Theodorakopoulou M, Georgiou A, Iatridi F, Karkamani E, Stamatiou A, Devrikis N et al (2024) Accuracy of 24 h ambulatory blood pressure recordings for diagnosing high 44 h blood pressure in hemodialysis: a diagnostic test study. Hypertens Res 47:1042–1050CrossRefPubMed
Metadata
Title
Beta-blockers in patients with intradialytic hypertension: are they potent anti-hypertensives?
Authors
Marieta Theodorakopoulou
Fotini Iatridi
Pantelis Sarafidis
Publication date
07-05-2024
Publisher
Springer Netherlands
Published in
International Urology and Nephrology
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-024-04073-x
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits